



Meeting Minutes
TPA Formulary Committee
February 11, 2022

Call to Order

The February 11, 2022, TPA-Formulary Committee was called to order at 2:02 p.m. at the Department of Health Professions (DHP), Perimeter Center, 9960 Mayland Drive, 2nd Floor, Board Room 4, Henrico, Virginia 23233.

Presiding Officer

Lisa Wallace-Davis, OD,

Members Present

Evan Kaufman, OD
Jonathan Noble, OD
Shawn Hobbs, OD
Cheryl Nelson, Pharmacist
William Bearden, MD
Suzanne Everhart, DO

Staff Present

Leslie Knachel, Executive Director
Elaine Yeatts, Senior Policy Analyst
Erin Barrett, Senior Policy Analyst
Laura Jackson, Board Administrator
Laura Paasch, Operations Administrative Assistant

Public Present

No public was present

Establishment of Quorum

With seven committee members present, a quorum was established.

Introduction of new Board Member and new Board staff

Members introduced themselves

Mission Statement

Dr. Wallace-Davis read the mission statement and thanked the Committee members for participating.

Ordering of Agenda

The Committee accepted the agenda as presented.

Public Comment

There were no requests to provide public comment.

Discussion Items

Dr. Wallace-Davis stated that the Committee is convening to consider the addition of two therapeutic drugs to the TPA-Formulary.

Leslie Knachel and Elaine Yeatts provided background information on the two drugs.

Drug 1: Pilocarpine hydrochloride ophthalmic solution 1.25%, a cholinergic muscarinic receptor agonist for the treatment of presbyopia in adults.

Drug 2: Varenicline solution nasal spray, a cholinergic agonist, for the treatment of signs and symptoms of dry eye disease.

The Committee discussed the two drugs including concerns about the drugs' side effects and limited trial studies.

Dr. Noble made a motion to recommend to the full board to add cholinergic agonists to the TPA-Formulary. Dr. Kaufman properly seconded the motion. The motion carried with four aye and three nay votes.

Next Steps

Dr. Wallace-Davis reviewed the next steps for the approved action taken by the Committee.

Adjournment

Hearing no objections, Dr. Wallace-Davis adjourned the meeting at 2:31 p.m.